[
1. Lu CC, Chen MY, Lee WS, Chang YL. Potential therapeutic agents against COVID-19: What we know so far. J Chin Med Assoc. 2020;83(6):534-6.10.1097/JCMA.0000000000000318717626632243270
]Search in Google Scholar
[
2. World Health Organization. Weekly epidemiological update on COVID-19 - 13 July 2021 [cited July 15, 2021]. In: World Health Organization [Internet]. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021
]Search in Google Scholar
[
3. Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A. Pharmacotherapy in COVID-19; A narrative review for emergency providers. Am. J. Emerg. Med. 2020;38(7):1488-93.10.1016/j.ajem.2020.04.035
]Search in Google Scholar
[
4. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir. Res. 2013;100(2):446-54.10.1016/j.antiviral.2013.09.015
]Search in Google Scholar
[
5. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil. Med. Res. 2020;7(1):11.10.1186/s40779-020-00240-0
]Search in Google Scholar
[
6. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. 2020;6(10), 1192-8.10.1016/j.eng.2020.03.007
]Search in Google Scholar
[
7. Çalık Başaran N, Uyaroğlu OA, Telli Dizman G, Özışık L, Şahin TK, Taş Z, et al. Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU. Turk. J. Med. Sci. 2021;51(2):411-20.10.3906/sag-2006-173
]Search in Google Scholar
[
8. Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv. 2020. DOI: https://doi.org/10.1101/2020.03.17.20037432
]Search in Google Scholar
[
9. Lou Y, Liu L, Yao H, Hu X, Su J, Xu K, et al. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial. Eur. J. Pharm. Sci. 2021;157.10.1016/j.ejps.2020.105631758571933115675
]Search in Google Scholar
[
10. Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN., еt al. AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020;ciaa1176.10.1093/cid/ciaa1176745438832770240
]Search in Google Scholar
[
11. Shrestha DB, Budhathoki P, Khadka S, Shah PB, Pokharel N, Rashmi P. (2020). Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virology Journal. 2020;17(1):141.10.1186/s12985-020-01412-z
]Search in Google Scholar
[
12. [Clinical protocol for the diagnosis and treatment of coronavirus infection COVID-19]. Protocol No. 107, Approved by the Joint Commission on the Quality of Medical Services of the Ministry of Health of the Republic of Kazakhstan dated July 15, 2020. Available from: www.gov.kz Russian.
]Search in Google Scholar
